Safety
DLTs, TRAEs
HYPERGLYCEMIA
In the 8 mg QD group, two patients experienced DLTs of grade 3 hyperglycemia. No DLTs were reported in other dose groups, indicating an MTD of 6 mg QD. The incidence rates of AEs and grade ≥3 AEs were 100% and 27.8%, respectively. TRAEs occurred in all patients, regardless of the drug dose (Table TRAEs occurring in ≥10% of patients.The median treatment exposure for HS‐10352 was 110.5 days (range, 12 to 525). The exposure duration was the longest in the 6 mg QD group (288.8 ± 140.73 days), which also had the highest cumulative exposure dose (1632.0 ± 793.67 mg) (Table 